We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
RCKT Stock Tanks on Patient Death in Danon Disease Study
Read MoreHide Full Article
Shares of Rocket Pharmaceuticals (RCKT - Free Report) plunged 62.8% on Tuesday after the company announced a patient death in a pivotal phase II study evaluating its investigational gene therapy candidate, RP-A501, for treating patients with Danon disease.
The company confirmed that one of the patients in the study experienced an acute systemic infection, an unexpected serious adverse event, which resulted in his untimely death.
Following the turn of events, RCKT has voluntarily paused further dosing in the study evaluating RP-A501 in Danon disease. Last week, the FDA placed a clinical hold on the study.
The company is currently carrying out a comprehensive root cause analysis to identify the reason for such an adverse event.
RCKT is working with the FDA, the Independent Data Safety Monitoring Committee, clinical investigators and scientific experts to restart the study as soon as possible, while ensuring the safety of all the patients in the study.
Per management, RP-A501 is the first gene therapy to demonstrate safety and efficacy in clinical studies for a cardiovascular condition.
RCKT's Stock Performance
Year to date, shares of Rocket Pharmaceuticals have plunged 81.5% compared with the industry’s decline of 5.8%.
Image Source: Zacks Investment Research
RCKT's Recent Pipeline Setbacks
Setbacks related to pipeline candidates have been a major concern for Rocket Pharmaceuticals in recent times.
The company is developing Kresladi to treat patients with severe leukocyte adhesion deficiency-I (LAD-I), a rare genetic disorder.
Last June, the FDA issued a complete response letter (CRL) to the biologics license application (BLA) seeking approval for Kresladi to treat LAD-I.
Per the CRL, the FDA sought "limited" additional information on the Chemistry Manufacturing and Controls (CMC), which is part of the BLA submission. The regulatory body is currently reviewing the limited additional CMC information for Kresladi.
This was the second time that the FDA had requested additional information from the company on Kresladi’s CMC. In February 2024, the FDA extended the review period of the Kresladi BLA by an additional three months.
The company is planning to file a complete BLA to resolve the CRL later in 2025.
RCKT's Zacks Rank & Stocks to Consider
Rocket Pharmaceuticals currently carries a Zacks Rank #3 (Hold).
In the past 60 days, estimates for Lexicon’s loss per share have narrowed from 37 cents to 32 cents for 2025. During the same time, loss per share estimates for 2026 have narrowed from 35 cents to 31 cents. Year to date, shares of LXRX have lost 6.6%.
LXRX’s earnings beat estimates in three of the trailing four quarters and missed the same on the remaining occasion, delivering an average surprise of 11.97%.
In the past 60 days, estimates for Chemomab Therapeutics’ loss per share have narrowed from 70 cents to 60 cents for 2025. During the same time, loss per share estimates for 2026 have narrowed from 80 cents to 70 cents. Year to date, shares of CMMB have declined 22.7%.
CMMB’s earnings beat estimates in two of the trailing four quarters, matched once and missed the same on the remaining occasion, delivering an average surprise of 5.00%.
In the past 60 days, estimates for Amarin’s loss per share have narrowed from $5.33 to $3.48 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $4.13 to $2.67. Year to date, shares of AMRN have gained 17.1%.
AMRN’s earnings beat estimates in two of the trailing four quarters, matched once and missed the same on the remaining occasion, delivering an average surprise of 29.11%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
RCKT Stock Tanks on Patient Death in Danon Disease Study
Shares of Rocket Pharmaceuticals (RCKT - Free Report) plunged 62.8% on Tuesday after the company announced a patient death in a pivotal phase II study evaluating its investigational gene therapy candidate, RP-A501, for treating patients with Danon disease.
The company confirmed that one of the patients in the study experienced an acute systemic infection, an unexpected serious adverse event, which resulted in his untimely death.
Following the turn of events, RCKT has voluntarily paused further dosing in the study evaluating RP-A501 in Danon disease. Last week, the FDA placed a clinical hold on the study.
The company is currently carrying out a comprehensive root cause analysis to identify the reason for such an adverse event.
RCKT is working with the FDA, the Independent Data Safety Monitoring Committee, clinical investigators and scientific experts to restart the study as soon as possible, while ensuring the safety of all the patients in the study.
Per management, RP-A501 is the first gene therapy to demonstrate safety and efficacy in clinical studies for a cardiovascular condition.
RCKT's Stock Performance
Year to date, shares of Rocket Pharmaceuticals have plunged 81.5% compared with the industry’s decline of 5.8%.
Image Source: Zacks Investment Research
RCKT's Recent Pipeline Setbacks
Setbacks related to pipeline candidates have been a major concern for Rocket Pharmaceuticals in recent times.
The company is developing Kresladi to treat patients with severe leukocyte adhesion deficiency-I (LAD-I), a rare genetic disorder.
Last June, the FDA issued a complete response letter (CRL) to the biologics license application (BLA) seeking approval for Kresladi to treat LAD-I.
Per the CRL, the FDA sought "limited" additional information on the Chemistry Manufacturing and Controls (CMC), which is part of the BLA submission. The regulatory body is currently reviewing the limited additional CMC information for Kresladi.
This was the second time that the FDA had requested additional information from the company on Kresladi’s CMC. In February 2024, the FDA extended the review period of the Kresladi BLA by an additional three months.
The company is planning to file a complete BLA to resolve the CRL later in 2025.
RCKT's Zacks Rank & Stocks to Consider
Rocket Pharmaceuticals currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Lexicon Pharmaceuticals (LXRX - Free Report) , Chemomab Therapeutics (CMMB - Free Report) and Amarin (AMRN - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, estimates for Lexicon’s loss per share have narrowed from 37 cents to 32 cents for 2025. During the same time, loss per share estimates for 2026 have narrowed from 35 cents to 31 cents. Year to date, shares of LXRX have lost 6.6%.
LXRX’s earnings beat estimates in three of the trailing four quarters and missed the same on the remaining occasion, delivering an average surprise of 11.97%.
In the past 60 days, estimates for Chemomab Therapeutics’ loss per share have narrowed from 70 cents to 60 cents for 2025. During the same time, loss per share estimates for 2026 have narrowed from 80 cents to 70 cents. Year to date, shares of CMMB have declined 22.7%.
CMMB’s earnings beat estimates in two of the trailing four quarters, matched once and missed the same on the remaining occasion, delivering an average surprise of 5.00%.
In the past 60 days, estimates for Amarin’s loss per share have narrowed from $5.33 to $3.48 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $4.13 to $2.67. Year to date, shares of AMRN have gained 17.1%.
AMRN’s earnings beat estimates in two of the trailing four quarters, matched once and missed the same on the remaining occasion, delivering an average surprise of 29.11%.